---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269470"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:46:40.807989+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aptevo reports 89% remission in frontline AML with mipletamig; Q3 net loss $7.5M

## Summary
- 89% of evaluable frontline AML patients achieved remission (CR+CRi) across two trials of mipletamig; no cytokine release syndrome observed.
- Introduced trispecific molecules APVO451 and APVO452 for solid tumors, expanding CD3 T-cell engager portfolio to five candidates.
- Raised $18.7M net in Q3 and additional $4.1M in October; proforma cash $25.2M extends runway into 4Q26.
- Q3 net loss $7.5M ($2.23 per share) vs $5.1M ($357.86 per share) in Q3 2024; R&D spend $4.0M, G&A $3.6M.

## SEC filing metadata
- accession: 0001193125-25-269470
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000119312525269470/0001193125-25-269470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000119312525269470/apvo-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269470
- JSON: https://secwatch.observer/filing/0001193125-25-269470.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269470.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.